Adenosylmethionine succinate, a new hepatobiliary drug from Zhenyuan, Zhejiang Province, is expected to obtain production approval in the first half of the year

According to the website of the State Food and Drug Administration (CFDA) on March 20, the three in one review of adenosylmethionine succinate bulk drug and injection, a new hepatobiliary drug declared and produced by Zhejiang Zhenyuan Co., Ltd., has been completed and the status has changed to "under approval" If there is no accident, Zhejiang Zhenyuan is expected to get the product production approval in the second quarter, when it will share the domestic market with Haizheng pharmaceutical, the first pharmaceutical imitator of the variety Zhejiang Zhenyuan related people have said that the product is an important specialty drug of the company, and will be promoted to the whole country through the combination of self-sale and agency after listing The price will be similar to that of Haizheng pharmaceutical industry, and there will be no vicious competition According to the official website of Zhenyuan subsidiary of Zhejiang Province, adenosylmethionine succinate raw materials and adenosylmethionine succinate for injection are the drugs that the company started to initiate research and development in 2004 In the course of ten years of research and development, the company has invested tens of millions of yuan in research and development and supporting production equipment and system costs If it is approved to be listed, it is very hopeful that it will reap heavy new strategic products for the company Species It is reported that adenosylmethionine succinate of Haizheng Pharmaceutical Co., Ltd achieved a revenue of more than 100 million yuan in the first half of 2013, with good sales volume Data show that adenosylmethionine is a kind of physiologically active molecule commonly existing in human tissues and body fluids, which is mainly suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, and can make the abnormal liver function caused by various reasons turn to normal At present, there is only one Haizheng pharmaceutical company in China that produces the product, and nearly 10 domestic enterprises have applied for the production of the product